iTeos Therapeutics (NASDAQ:ITOS) Stock Rating Reaffirmed by HC Wainwright

iTeos Therapeutics (NASDAQ:ITOS)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research report issued on Monday, Benzinga reports. They presently have a $46.00 price target on the stock. HC Wainwright’s price target would indicate a potential upside of 279.69% from the company’s previous close.

Other research analysts have also issued reports about the stock. Wells Fargo & Company initiated coverage on shares of iTeos Therapeutics in a report on Tuesday, August 13th. They issued an “overweight” rating and a $31.00 target price for the company. JPMorgan Chase & Co. dropped their price objective on shares of iTeos Therapeutics from $27.00 to $24.00 and set an “overweight” rating for the company in a research note on Monday, August 12th. Finally, Wedbush restated an “outperform” rating and issued a $21.00 target price on shares of iTeos Therapeutics in a report on Thursday, August 8th.

iTeos Therapeutics Stock Up 0.1 %

ITOS opened at $12.12 on Monday. The company has a market capitalization of $437.63 million, a PE ratio of -3.21 and a beta of 1.39. The firm has a 50-day simple moving average of $16.19 and a two-hundred day simple moving average of $14.65. iTeos Therapeutics has a 52 week low of $8.20 and a 52 week high of $18.75.

iTeos Therapeutics (NASDAQ:ITOS) last posted its earnings results on Thursday, August 8th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($1.04) by $0.86. The firm had revenue of $35.00 million during the quarter, compared to analysts’ expectations of $4.20 million. As a group, sell-side analysts expect that iTeos Therapeutics will post -4.21 earnings per share for the current year.

Institutional Trading of iTeos Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. Russell Investments Group Ltd. raised its position in iTeos Therapeutics by 66.3% in the 4th quarter. Russell Investments Group Ltd. now owns 39,508 shares of the company’s stock worth $433,000 after purchasing an additional 15,757 shares during the period. Jump Financial LLC purchased a new stake in shares of iTeos Therapeutics in the fourth quarter worth approximately $636,000. Dynamic Technology Lab Private Ltd lifted its stake in shares of iTeos Therapeutics by 357.2% during the 4th quarter. Dynamic Technology Lab Private Ltd now owns 47,461 shares of the company’s stock worth $520,000 after acquiring an additional 37,080 shares during the last quarter. Trexquant Investment LP boosted its holdings in iTeos Therapeutics by 83.8% during the 4th quarter. Trexquant Investment LP now owns 61,658 shares of the company’s stock valued at $675,000 after acquiring an additional 28,109 shares during the period. Finally, Quest Partners LLC bought a new position in iTeos Therapeutics in the 4th quarter valued at $90,000. 97.16% of the stock is currently owned by institutional investors.

About iTeos Therapeutics

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.